Iron overload disorders: Natural history, pathogenesis, diagnosis, and therapy

Critical Reviews in Clinical Laboratory Sciences

Volumn 19, Issue 3, 1983, Pages 205-266

  Mclaren, Gordon D ^a   Muir, W Angus ^a   Kellermeyer, Robert W ^a   Jacobs, Allan ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; FERRITIN; HLA ANTIGEN; IRON; TRANSFERRIN;

ALCOHOL LIVER CIRRHOSIS; BLOOD; BLOOD TRANSFUSION; DISEASE MODEL; GENETIC LINKAGE; GENETICS; HEMOCHROMATOSIS; HEMODIALYSIS; HEMOSIDEROSIS; HUMAN; INTESTINE ABSORPTION; IRON DEFICIENCY ANEMIA; LIVER CIRRHOSIS; METABOLISM; NUTRITIONAL DEFICIENCY; PEDIGREE; PHLEBOTOMY; PORPHYRIA; RETICULOENDOTHELIAL SYSTEM; REVIEW; THALASSEMIA; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; URINE;

ANEMIA, HYPOCHROMIC; BIOLOGICAL TRANSPORT; BLOOD TRANSFUSION; BLOODLETTING; CHELATING AGENTS; DEFEROXAMINE; DISEASE MODELS, ANIMAL; FERRITIN; HEMOCHROMATOSIS; HEMOSIDEROSIS; HLA ANTIGENS; HUMAN; INTESTINAL ABSORPTION; IRON; LINKAGE (GENETICS); LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; PEDIGREE; PORPHYRIA; RENAL DIALYSIS; RETICULOENDOTHELIAL SYSTEM; SUPPORT, U.S. GOV'T, P.H.S.; THALASSEMIA; TISSUE DISTRIBUTION; TRANSFERRIN;

EID: 0021000035     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408368309165764     Document Type: Article

References (398)

1. Haemochromatosis and iron overload
2. Idiopathic haemochromatosis
3. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis
4. Changing concepts in haemochromatosis
5. Iron storage disorders of the liver
6. Hemochromatosis: the unsolved problems
7. Hemochromatosis: 1980 update
8. Iron overload
9. Ferritin and haemosiderin: structure and function
10. Hemosiderin: nature, formation, and significance
11. Glycosurie, diabète sucré
12. Diabète sucré
13. Ueber Hämochromatose
14. Idiopathic hemochromatosis. A variant of portal cirrhosis and idiopathic hemosiderosis
15. Idiopathic hemochromatosis: acquired or inherited?
16. Idiopathic hemochromatosis: demonstration of recessive transmission and early detection by family HLA typing
17. Hereditary hemochromatosis; phenotypic expression of the disease
18. Siderosis in the Bantu of Southern Africa
19. Idiopathic and Bantu hemochromatosis. Comparative histological study
20. Iron uptake and haemochromatosis in Bantu
21. Siderosis in the Bantu. A combined histopathological and chemical study
22. Siderosis in the Bantu: the clinical incidence of hemochromatosis in diabetic subjects
23. Hepatic sinusoidal cells in iron overload: ultrastructural observations
24. Idiopathic haemochromatosis in children. Report of a family
25. Hemochromatosis: pathologic and genetic considerations
26. Idiopathic hemochromatosis in young subjects. Clinical, pathological and chemical findings in four patients
27. Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people
28. Liver biopsy in diagnosis of hemochromatosis
29. The reversal of hemochromatotic cirrhosis by multiple phlebotomies. Report of a case
30. The treatment of hemochromatosis by phlebotomy
31. Reversal of “cirrhosis” in idiopathic haemochromatosis following long-term intensive venesection therapy
32. Long-term results of venesection therapy in idiopathic haemochromatosis
33. Primary carcinoma of the liver in hemochromatosis
34. Primary carcinoma of the liver; study of 100 cases among 48,900 necropsies
35. Hemochromatosis and hemosiderosis. Study of 211 autopsied cases
36. Hepatoma developing in treated hemochromatosis. Report of a case
37. Hepatoma developing in hemochromatosis in spite of adequate treatment by multiple phlebotomies
38. Normal and abnormal regulation of β-MSH in man
39. Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis
40. Insulin-resistant diabetes mellitus associated with hemochromatosis
41. Action of prednisone in insulin-resistant diabetes
42. Iron excess, early glucose intolerance and impaired insulin secretion in idiopathic hemochromatosis
43. Familial hemochromatosis: characteristics of the pre-cirrhotic stage in a large kindred
44. Occurrence and prevalence of diabetic retinopathy in hemochromatosis
45. Quatre observations de pancréatite calcifiante dans l'hémochromatose
46. Idiopathic hemochromatosis presenting as malabsorption syndrome
47. Pituitary function in haemochromatosis
48. Endocrine abnormalities in chronic liver disease
49. Pituitary function in idiopathic haemochromatosis and cirrhosis of the liver
50. An investigation into gonadal dysfunction in patients with idiopathic hemochromatosis
51. Hemochromatosis: investigation of 23 cases, with special reference to etiology, nutrition, iron metabolism, and studies of hepatic and pancreatic function
52. Hemochromatosis and arthritis
53. Synovial biopsy in haemochromatosis arthropathy: histological findings and iron deposition in relation to total body iron overload
54. Hemochromatosis: a disease often silent but not invisible
55. Unusual connective tissue manifestations of hemochromatosis
56. Hemochromatotic arthropathy mimicking rheumatoid arthritis. A case with subcutaneous nodules, tenosynovitis, and bursitis
57. The arthropathy of hemochromatosis without hemochromatosis
58. Arthropathy as the major clinical indicator of occult iron storage disease
59. Arthritis in hemochromatosis. A case report
60. Arthropathy, hypouricemia and normal serum iron studies in hereditary hemochromatosis
61. Arthropathy of hemochromatosis
62. Hemochromatosis and arthritis
63. The natural history of arthritis in idiopathic haemochromatosis: progression of the clinical and radiological features over ten years
64. Osteoporosis, scurvy, and siderosis in Johannesburg Bantu
65. Effects of iron overload on ascorbic acid metabolism
66. Scurvy and altered iron stores in thalassemia major
67. Accelerated oxidative catabolism of ascorbic acid in siderotic Bantu
68. Ascorbic acid catabolism in Bantu with hemosiderosis (scurvy)
69. The effect of siderosis and ascorbic acid depletion on bone metabolism, with special reference to osteoporosis in the Bantu
70. Some aspects of calcium metabolism in normal and osteoporotic Bantu subjects with special reference to the effects of iron overload and ascorbic acid depletion
71. The heart in hemochromatosis
72. Iron in the heart
73. The treatment of haemochromatosis; with particular reference to the removal of iron from the body by repeated venesection
74. Hemochromatosis and heart failure: presentation of a case with survival after three years' treatment by repeated venesection
75. Reversible cardiomyopathy associated with hemochromatosis
76. Haemochromatosis presenting as congestive cardiomyopathy and responding to venesection
77. Clinical consequences of acquired transfusional iron overload in adults
78. Iron absorption in the thalassemia syndromes and its inhibition by tea
79. Acute abdominal pain and shock associated with hemochromatosis
80. Acute abdominal crisis, circulatory collapse and sudden death in haemochromatosis
81. Pasteurella pseudotuberculosis Acute sepsis with survival
82. Iron and infection
83. Iron and susceptibility to infectious disease
84. Iron and susceptibility to infectious disease
85. Increased incidence of Gram-negative neonatal sepsis with intramuscular iron administration
86. Immunity, transferrin, and survival in kwashiorkor
87. Iron deficiency anemia of infancy. Some clinical principles illustrated by response of Maori infants to neonatal parenternal iron administration
88. Disease caused by a marine Vibrio: clinical characteristics and epidemiology
89. Suppressive effect of ferritin on in vitro lymphocyte function
90. Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload
91. Iron uptake and ferritin synthesis by human peripheral blood monotypes incubated in vitro with a particulate suspension of radioiron
92. Idiopathic hemochromatosis, an interim report
93. Suppression of hematopoiesis by ethanol
94. Hemochromatosis, hepatoma, erythrocytosis and erythropoietin
95. Hepatoma, erythrocytosis, and increased serum erythropoietin in long-standing hemochromatosis
96. Clinical evaluation of iron stores
97. Iron metabolism and hemochromatosis
98. Patterns of iron storage in dietary iron overload and idiopathic hemochromatosis
99. High incidence of extrahepatic carcinomas in idiopathic hemochromatosis
100. Congenital transferrin deficiency in a 7-year-old girl
101. A family of congenital atransferrinemia
102. Generalized siderosis with fibrosis of the liver and pancreas in Cooley's (Mediterranean) Anemia
103. Hereditary iron loading anemia with secondary hemochromatosis
104. A familial study in idiopathic hemochromatosis
105. Hemochromatose juvenile chez trois soeurs et un frère avec consanguinité des parents
106. Liver histology in six asymptomatic siblings in a family with hemochromatosis. Genetic implications
107. Hepatic pathology in relatives of patients with hemochromatosis
108. Familial occurrence of hemochromatosis
109. Familial aspects of idiopathic hemochromatosis
110. Haemochromatosis, a family study
111. Hemochromatosis in a family
112. Konkordantes auftreten von lebercirrhose und diabetes mellitus (hämochromatose) bei eineiigen zwillingen
113. Hemochromatosis in two young sisters. Case studies and a family survey
114. Genetics of haemochromatosis
115. The metabolism of iron in haemochromatosis
116. Idiopathic hemochromatosis: a study of three families
117. Inheritance of haemochromatosis: a report on a family with consanguinity
118. Familial hemochromatosis: physiologic studies in the precirrhotic stage of the disease
119. Hereditary hemochromatosis: diagnosis in siblings and children
120. Idiopathic hemochromatosis associated with HL-A3 tissular antigen
121. HLA antigens in haemochromatosis
122. HLA antigens in haemochromatosis
123. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis
124. Inheritance of idiopathic haemochromatosis
125. Idiopathic hemochromatosis and iron overload in alcoholic liver disease: differentiation by HLA phenotype
126. Hereditary hemochromatosis: dominant inheritance and probable linkage to HLA
127. Idiopathic hemochromatosis: linkage with HLA
128. Serum ferritin as a possible marker of the hemochromatosis allele
129. Genetic mapping of the hemochromatosis locus on chromsome six
130. Hepatic cirrhosis: a clinico-pathologic review of 520 cases
131. The genetics of hemochromatosis
132. Genetics of hemochromatosis
133. Histocompatibility antigens as markers of abnormal iron metabolism in patients with idiopathic haemochromatosis and their relatives
134. Idiopathic hemochromatosis: a study of biochemical expression in 247 heterozygous members of 63 families: evidence for a single major HLA-linked gene
135. Atrioventricular block in familial hemochromatosis treated by permanent synchronous pacemaker
136. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis
137. Hepatic siderosis and porphyria cutanea tarda: relation of iron excess to the metabolic defect
138. Porphyria cutanea tarda: clinical features and laboratory findings in 40 patients
139. Treatment of porphyria cutanea tarda by phlebotomy
140. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity
141. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda
142. Decreased hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda
143. The enzymatic defect in porphyria cutanea tarda
144. Red-cell uroporphyrinogen decarboxylase activity in porphyria cutanea tarda and in other forms of porphyria
145. The role of iron in the pathogenesis of porphyria cutanea tarda. II. Inhibition of uroporphyrinogen decarboxylase
146. Porphyria cutanea tarda in three generations of a single family
147. HLA-types in porphyria cutanea tarda
148. Iron-overload-associated myopathy in patients on maintenance haemodialysis: a histocompatibility-linked disorder
149. Iron absorption and iron overload
150. Ferritin iron absorption in man
151. Iron absorption from ingested pork, hog-liver and hemoglobin in subjects with normal and depleted iron stores. Studies on dietary iron prophylaxis and therapy
152. Clinical aspects of iron absorption and turnover
153. Gastric intrinsic factor and iron absorption
154. Site of iron absorption in man
155. Absorption and excretion of iron
156. Ferritin: its properties and significance for iron metabolism
157. Mechanism of iron absorption: iron-binding proteins and dependence of iron absorption on an elutable factor
158. Morphological findings in iron absorption
159. Internal regulation of iron absorption
160. Regulation of iron absorption and storage iron turnover
161. Iron absorption in idiopathic haemochromatosis before, during, and after venesection therapy
162. Iron absorption in normal subjects and patients with idiopathic haemochromatosis: relationship with serum ferritin concentration
163. Relationship of disturbed pancreatic function to haemosiderosis
164. Relationship of diminished pancreatic secretion to haemochromatosis
165. Does the pancreas influence iron absorption? A critical review of information to date
166. The effect of enteral and parenteral iron on ferritin synthesis in the intestinal mucosa of the rat
167. Reduction of gastric iron-binding protein in haemochromatosis, a previously unrecognized metabolic defect
168. Gastric iron binding in haemochromatosis, secondary iron overload, cirrhosis, and diabetes
169. Gastric iron binding substance (gastroferrin) in a family with haemochromatosis
170. Iron binding properties of gastric juice in idiopathic haemochromatosis
171. Studies on an iron-binding component in human gastric juice
172. In vivo intestinal mucosal uptake of iron, body iron and absorption and gastric juice iron-binding in idiopathic haemochromatosis
173. The control of iron balance by the intestinal mucosa
174. The iron content of jejunal mucosa obtained by Crosby's biopsy in hemochromatosis and hemosiderosis
175. 4
176. Intestinal mucosal uptake of iron and iron retention in idiopathic haemochromatosis as evidence for a mucosal abnormality
177. Xanthinuria and hemochromatosis
178. Mechanism of release of ferritin iron in vivo by xanthine oxidase
179. Absorption of hemoglobin iron: the role of xanthine oxidase in the intestinal heme-splitting reaction
180. Effect of xanthine oxidase inhibitor (allopurinol) on radioiron absorption in man
181. The kinetics of iron uptake in vitro by human duodenal mucosa: studies in normal subjects
182. Cellular mechanisms in the regulation of iron absorption by the human intestine: studies in patients with iron deficiency before and after treatment
183. Uptake of iron by duodenal biopsy specimens from patients with iron-deficiency anaemia and primary haemochromatosis
184. In vitro studies of duodenal iron uptake in patients with primary and secondary iron storage disease
185. Prevalence of the hemochromatosis gene
186. Mucosal uptake, mucosal transfer, and retention of iron, measured by whole body counting
187. Iron kinetics with emphasis on iron overload
188. In vivo evidence for the functional heterogeneity of transferrin-bound iron. III. Studies of transferrin at high and low saturation
189. Effect of iron saturation of transferrin on hepatic iron uptake: an in vitro study
190. The iron-binding function of transferrin in iron metabolism
191. Differences between the binding sites for iron binding and release in human and rat transferrin
192. Circadian variation in plasma iron concentration and reticuloendothelial iron release in the rat
193. Diurnal variations of the serum iron in normal subjects and in patients with haemochromatosis
194. A transferrin variant with unusual iron-binding properties
195. Studies on the behaviour of transferrin in idiopathic haemochromatosis
196. A nontransferrin-bound serum iron in idiopathic hemochromatosis
197. Nonspecific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity
198. Iron kinetics and erythropoiesis
199. Hepatic iron clearance from serum in treated hemochromatosis
200. Transient hepatic deposition of iron in primary hemochromatosis with iron deficiency following venesection
201. Hepatic iron deposition in humans
202. Distribution of storage iron as body iron stores expand in patients with hemochromatosis
203. Transferrin metabolism and the liver
204. Ferritin: molecular structure and iron-storage mechanisms
205. Ferritin structure and function
206. Ferritin: comparative structural studies, iron deposition, and mobilization
207. Iron overload—clinical and pathologic aspects
208. The pathology of iron overload
209. Ferritin: an iron-storage molecule
210. Human isoferritins in normal and disease states
211. Metabolic and molecular heterogeneity of marrow ferritin
212. Properties of human tissue isoferritins
213. The reactivity of isoferritins in a labelled antibody assay
214. Changes in the characteristics and distribution of ferritin in iron-loaded cell cultures
215. Ferritin phenotypes: structure and metabolism
216. The organ-specificity of ferritin in human and horse liver and spleen
217. Abnormality in tissue isoferritin distribution in idiopathic haemochromatosis
218. Alterations in tissue ferritins in iron storage disorders
219. Ferritin biosynthesis. II. Acceleration of synthesis by the administration of iron
220. In vitro stimulation of apoferritin synthesis by iron
221. Low molecular weight intracellular iron transport compounds
222. Iron and the reticuloendothelial system
223. Transferrin iron, chelatable iron and ferritin in idiopathic haemochromatosis
224. Tissue iron distribution in idiopathic hemochromatosis
225. Studies on the concentration and intracellular localization of iron proteins in liver biopsy specimens from patients with iron overload with special reference to their role in lysosomal disruption
226. Duodenal ferritin content and structure: relationship with body iron stores in man
227. Iron uptake and ferritin synthesis by peripheral blood leucocytes in patients with primary idiopathic haemochromatosis
228. Ferritin synthesis in peripheral blood monocytes in idiopathic hemochromatosis
229. The pathology of the liver in hemochromatosis
230. Assessment of bone marrow and body iron stores: old techniques and new technologies
231. The quantitative estimation of total iron stores in human bone marrow
232. Histogenesis of the hepatic lesion in primary hemochromatosis: with consideration of the pseudo-iron deficient state produced by phlebotomies
233. Diagnostic value of marrow hemosiderin patterns
234. Diagnostic value of bone marrow iron deposits in idiopathic hemochromatosis
235. Studies of experimental hemochromatosis: disorder of the reticuloendothelial system and excess iron
236. Decreased uptake of iron by peripheral blood monocytes from patients with hereditary hemochromatosis. A clue to etiology?
237. Haemochromatosis and superoxide metabolism: free-radical influenced iron storage?
238. Storage iron regulation
239. The measurement of iron absorption by the double isotope technique
240. Iron absorption in idiopathic haemochromatosis and its measurement using a whole-body counter
241. Patterns of food iron absorption in iron-deficient white and Indian subjects and in venesected haemochromatotic patients
242. Iron absorption in hemochromatosis before and after phlebotomy therapy
243. Iron absorption studies in idiopathic haemochromatosis
244. Ultrastructural characteristics of the synovial membrane in idiopathic haemochromatosis
245. Ferritin in synovial cells in patients with rheumatoid arthritis
246. Circulating iron-containing macrophages in hemochromatosis
247. Monocyte ferritin levels disproportionately low in untreated idiopathic hemochromatosis
248. Idiopathic hemochromatosis (IH). Abnormality in RBC transport of iron by the reticuloendothelial system (RES)
249. A method for the investigation of reticuloendothelial iron kinetics in man
250. Morphological types of non-heme iron in bone marrow squash preparations and intestinal iron absorption
251. Iron and the macrophage. The monocyte is a metabolic idiot
252. Studies in iron transportation and metabolism. X. Long-term iron overload in dogs
253. Effect of ethionine-induced pancreatic damage on iron absorption
254. Experimental pigment cirrhosis: its production in rats by feeding a choline deficient diet with excess iron
255. Experimental hemochromatosis in rats
256. Iron metabolism by reticuloendothelial cells in vitro: physical and chemical conditions, lipotrope deficiency, and acute inflammation
257. Parenteral iron overload. Organ and cell distribution in rats
258. Iron metabolism by reticuloendothelial cells: in vitro uptake of transferrin-bound iron by rat and rabbit cells
259. Experimental hepatic cirrhosis in dogs caused by chronic massive iron overload
260. Effects of cyclic starvation—feeding and of splenectomy on the development of hemosiderosis in rat livers
261. Canine hemochromatosis: a model for the study of reticuloendothelial cell function
262. Animal model for hemochromatosis: hereditary susceptibility to hepatocellular iron overload
263. Atherosclerosis and arteriosclerosis in dogs following ingestion of cholesterol and thiouracil
264. Thyroidectomy increases rat hepatic ferritin iron
265. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis
266. Iron nitrilotriacetate-induced experimental diabetes in rats
267. The iron-loaded cell—the cytopathology of iron storage
268. Biochemical changes in the tissues of animals injected with iron. 3. Lipid peroxidation
269. Lysosomal changes in human and experimental iron overload
270. Acid hydrolase activities and lysosomal integrity in liver biopsies from patients with iron overload
271. Lipid peroxide formation in microsomes. The role of non-haem iron
272. Mechanisms of lipid peroxide formation in animal tissues
273. The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion
274. Hepatic lipid peroxidation in vivo in rats with chronic iron overload
275. Metabolic consequences of iron overload
276. Transferrin behaviour in primary haemochromatosis
277. Effects of desferrioxamine in patients with iron-loading with a simple method for estimating urinary iron
278. Measurement of iron stores using deferoxamine
279. Differential ferrioxamine test in idiopathic haemochromatosis and transfusional haemosiderosis
280. Use of diethylenetriamine penta-acetic acid (D.T.P.A.) in the clinical assessment of total body iron stores
281. Evaluation of storage iron by chelates
282. Differential ferrioxamine test in haemochromatosis and liver disease
283. The differential ferrioxamine test in the management of idiopathic haemochromatosis
284. Quantitative measurement of iron stores with diethylenetriamine penta-acetic acid
285. Measurement of iron stores in cirrhosis using diethylenetriamine penta-acetic acid
286. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload
287. Measurement of serum ferritin by a 2-site immunoradiometric assay
288. Solid phase radioimmunoassay for serum ferritin
289. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload
290. A clinical evaluation of serum ferritin as an index of iron stores
291. Ferritin in serum: diagnosis of iron deficiency and iron overload in infants and children
292. Serum ferritin assay
293. Serum ferritin
294. Normal” serum ferritin - a caution
295. New kinetic role for serum ferritin in iron metabolism
296. The characteristics of ferritin from human tissues, serum and blood cells
297. Characterization of serum ferritin in iron overload: possible identity to natural apoferritin
298. On the iron content of human serum ferritin, especially in acute viral hepatitis and iron overload
299. Ferritin turnover in plasma: an opportunistic use of blood removed during exchange transfusion
300. 131I-human plasma ferritin in man
301. The kinetics of serum ferritin
302. Ferritin synthesis by free and membrane-bound (poly) ribosomes of rat liver
303. The kinetics of serum and tissue ferritins: relation to carbohydrate content
304. Immunological detection of isoferritins in normal human serum and tissue
305. Some properties of human serum ferritin
306. Serum ferritin in haemochromatosis: changes in the isoferritin composition during venesection therapy
307. Binding of human serum ferritin to concanavalin A
308. Sialic acid and the microheterogeneity of human serum ferritin
309. Binding of serum ferritin to concanavalin A: patients with homozygous β thalassaemia and transfusional iron overload
310. Serum ferritin in patients with iron overload and with acute and chronic liver diseases
311. Serum ferritin concentration and iron stores in normal subjects
312. Serum ferritin in children with thalassaemia regularly transfused
313. Relationship between serum ferritin and total body iron stores in idiopathic haemochromatosis
314. Ferritin: clinical aspects
315. Variability of serum ferritin concentration in normal subjects
316. Serum ferritin and the iron status of Canadians
317. Regulation of plasma ferritin by the isolated perfused rat liver
318. Hepatic and serum ferritin concentrations in patients with idiopathic hemochromatosis
319. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods
320. Serum ferritin in ascorbic acid deficiency
321. Normal serum ferritin concentrations in precirrhotic hemochromatosis
322. Serum-ferritin in diagnosis of haemochromatosis. A study of 43 families
323. Early detection of idiopathic haemochromatosis: relative value of serum-ferritin and HLA typing
324. Clinical measurements of iron absorption
325. The relationship between marrow iron stores, plasma ferritin concentrations and iron absorption
326. Clinical and biochemical expression of the genetic abnormality in idiopathic hemochromatosis
327. Iron metabolism in haemochromatosis with reference to a chelatable iron pool and changes in iron absorption
328. Alteration of cobalt absorption in portal cirrhosis and idiopathic hemochromatosis
329. Serum ferritin, cobalt excretion and body iron status
330. A family study of a patient with idiopathic hemochromatosis
331. Significance for the diagnosis of iron overload of histo-chemical and chemical iron in the liver of normal subjects
332. Relationship of hepatic iron concentration to histochemical grading and to total chelatable body iron in conditions associated with iron overload
333. Measurement of liver-iron concentration in needle-biopsy specimens
334. Magnetic-susceptibility measurement of human iron stores
335. Computed tomography in the diagnosis of disorders of excessive iron storage of the liver
336. Correlation between computed tomographic values and liver iron content in thalassaemia major with iron overload
337. Computed tomography for determining liver iron content in primary haemochromatosis
338. Early idiopathic hemochromatosis with absent stainable bone marrow iron stores
339. Hemochromatosis and the skin
340. Cutaneous manifestations of idiopathic hemochromatosis
341. A noninvasive method for the evaluation of tissue iron deposition in beta-thalassemia major
342. Venesection therapy in idiopathic haemochromatosis: An analysis of 40 treated and 18 untreated patients
343. Serum ferritin
344. Storage iron measurement in hemochromatotic patients reaccumulating iron
345. Iron-containing growth factors, the sideramines, and their antagonists, the iron-containing sideromycin antibiotics
346. Long-term desferrioxamine therapy in thalassemia
347. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress
348. Reassessment of the use of desferrioxamine B in iron overload
349. Continuous subcutaneous administration of desferrioxamine in patients with iron overload
350. Effect of dose, time, ascorbate on iron excretion after subcutaneous desferrioxamine
351. Prevention of iron loading in transfusion-dependent thalassaemia
352. Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults
353. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects
354. The site of action of desferrioxamine
355. Mechanism of iron chelation in the hypertransfused rat; definition of two alternate pathways of iron mobilization
356. Chronic iron overload: new chelators and new strategies
357. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine
358. Response to long-term deferoxamine therapy in thalassemia
359. Chelation therapy in β-thalassemia major. III. The role of splenectomy in achieving iron balance
360. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major
361. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload
362. Chelation therapy for the treatment of thalassemia
363. Transfusion siderosis and chelation therapy
364. Iron chelation with oral desferrioxamine
365. Iron chelation with oral desferrioxamine
366. Oral desferrioxamine in young patients with thalassaemia
367. Chelation studies with 2,3-dihydroxybenzoic acid in patients with β-thalassaemia major
368. Inhibition of membrane peroxidation in thalassaemic erythrocytes by 2,3-dihydroxybenzoic acid
369. Effect of trisodium calcium diethylenetriaminepentaacetate on bivalent cations in thalassemia major
370. The identification of rhodotorulic acid as a potentially useful iron-chelating drug
371. The development of new iron-chelating drugs
372. The development of new iron-chelating drugs. II
373. The selection and evaluation of new chelating agents for the treatment of iron overload
374. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone
375. The inorganic chemistry of iron metabolism
376. Synergistic effect of nitrilotriacetate on iron mobilization by desferrioxamine in vivo
377. Liposome entrapped desferrioxamine and iron transporting ionophores: a new approach to iron chelation therapy
378. encapsulated desferrioxamine in experimental iron overload
379. Enhancement of iron chelation by desferrioxamine entrapped in red blood cell ghosts
380. Clinical trial of desferrioxamine entrapped in red cell ghosts
381. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen
382. Erythropoiesis and the effect of transfusion in homozygous β-thalassemia
383. Selective isolation of young erythrocytes for transfusion support of thalassemia major patients
384. A simple technique for preparation of young red cells for transfusion from ordinary blood units
385. Evidence and mechanism for pectin-reduced intestinal inorganic iron absorption in idiopathic hemochromatosis
386. Human ferritin gene is assigned to chromosome 19